Key result
Histological good response to osteosarcoma chemotherapy is linked to ~31% greater SUVmax reduction on PET/CT.
Why the study?
Continuation of ineffective neoadjuvant chemotherapy in osteosarcoma may lead to resistant clones and delay surgery, but conventional imaging criteria correlate poorly with histological necrosis.
Comparison
Conventional diagnostic imaging modalities vs 18F-FDG PET/CT for assessing neoadjuvant chemotherapy effect
Design
Observational study
Authors
Loading...
May support PET/CT for early response assessment in osteosarcoma; leaves open prospective validation before guiding therapy.
Observational (n=18)
No
Absolute Event Rate: 73% vs 42%
p-value: p=0.041
Joo et al. (2014) conducted an observational in Osteosarcoma (n=18). 18F-FDG PET/CT SUVmax reduction rate vs. Histological poor responders was evaluated on Difference in median SUVmax reduction rate between histological good responders and poor responders (p=0.041). The median SUVmax reduction rate on PET/CT was significantly higher in histological good responders (73%) compared to poor responders (42%, p=0.041) following neoadjuvant chemotherapy for osteosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: